Restless Leg Syndrome Treatment via NMDA and Opioid Combination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medications for restless leg syndrome often require high doses to be effective, leading to severe side effects that limit their use in the general population, necessitating the development of compositions with fewer side effects and improved efficacy.
Innovation Solution
Pharmaceutical compositions comprising a NMDA antagonist, a CYP2D6 inhibitor, and an opioid agonist, such as dextromethorphan, quinidine, and oxycodone, which are administered simultaneously or in combination to treat restless leg syndrome, reducing the need for high opioid agonist doses and minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of opioid agonists are used to treat restless leg syndrome, then therapeutic efficacy is improved, but side effects increase
Solution Approach 1:
The patent combines three distinct pharmacological agents (NMDA antagonist, CYP2D6 inhibitor, and opioid agonist) into a single pharmaceutical composition. This combination allows the opioid agonist to be administered at lower doses while maintaining therapeutic efficacy, thereby reducing side effects. The synergistic interaction between the three components addresses the technical contradiction by achieving both improved reliability and reduced harmful factors.
Solution Approach 2:
The NMDA antagonist and CYP2D6 inhibitor act as intermediary substances that modulate the pharmacological activity of the opioid agonist. The NMDA antagonist reduces central sensitization and pain transmission, while the CYP2D6 inhibitor prevents rapid metabolism of the opioid agonist, allowing lower doses to achieve therapeutic effects and thereby reducing side effects.
2Reliability
If high doses of medications are increased to overcome inefficiency, then therapeutic effect is improved, but severe side effects prevent effective use in general population
Solution Approach 1:
The patent merges three pharmacologically active components into a unified composition that works synergistically. The NMDA antagonist addresses central pain mechanisms, the CYP2D6 inhibitor optimizes drug metabolism, and the opioid agonist provides analgesia at lower doses. This combination resolves the contradiction by achieving reliable therapeutic effects without the severe side effects associated with high-dose monotherapy.
Solution Approach 2:
The pharmaceutical composition represents a composite therapeutic agent combining three different drug classes. This composite approach allows each component to contribute its unique pharmacological properties, achieving enhanced therapeutic effect at lower overall doses and thereby reducing severe side effects that would prevent use in the general population.
3Object-affected harmful factors
If opioid agonist doses are reduced to minimize side effects, then safety is improved, but efficacy decreases
Solution Approach 1:
The patent combines three agents that work through different mechanisms to achieve synergistic analgesia. The NMDA antagonist blocks pain transmission at the central level, the CYP2D6 inhibitor extends the half-life and potency of the opioid agonist, and the opioid agonist provides direct pain relief. This combination allows lower opioid doses to maintain efficacy while reducing side effects.
Solution Approach 2:
The CYP2D6 inhibitor changes the metabolic parameter of the opioid agonist by blocking its degradation pathway. This parameter change increases the bioavailability and duration of action of the opioid agonist, allowing lower doses to achieve the same therapeutic effect and thereby maintaining efficacy while minimizing side effects.
Data Source
AI summary
Embodiments disclosed herein describe, amongst other things, dosage forms, compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, restless leg syndrome.